These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22986987)

  • 1. Isolation and characterization of degradation products of moxidectin using LC, LTQ FT-MS, H/D exchange and NMR.
    Awasthi A; Razzak M; Al-Kassas R; Greenwood DR; Harvey J; Garg S
    Anal Bioanal Chem; 2012 Nov; 404(8):2203-22. PubMed ID: 22986987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Separation and identification of degradation products in eprinomectin formulation using LC, LTQ FT-MS, H/D exchange, and NMR.
    Awasthi A; Razzak M; Al-Kassas R; Greenwood DR; Harvey J; Garg S
    J Pharm Biomed Anal; 2012 Apr; 63():62-73. PubMed ID: 22341479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical profile of moxidectin.
    Awasthi A; Razzak M; Al-Kassas R; Harvey J; Garg S
    Profiles Drug Subst Excip Relat Methodol; 2013; 38():315-66. PubMed ID: 23668407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
    Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
    J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification, isolation and characterization of potential process-related impurity and its degradation product in vildagliptin.
    Kumar N; Devineni SR; Singh G; Kadirappa A; Dubey SK; Kumar P
    J Pharm Biomed Anal; 2016 Feb; 119():114-21. PubMed ID: 26678178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of degradation products of irbesartan using LC-MS/TOF, MS(n), on-line H/D exchange and LC-NMR.
    Shah RP; Sahu A; Singh S
    J Pharm Biomed Anal; 2010 Apr; 51(5):1037-46. PubMed ID: 20018473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification, isolation and characterization of a new degradation product in sultamicillin drug substance.
    Kumar VJ; Gupta PB; Kumar KS; Ray UK; Sreenivasulu B; Kumar GS; Rao KR; Sharma HK; Mukkanti K
    J Pharm Biomed Anal; 2011 Feb; 54(3):582-7. PubMed ID: 20934824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of LC-MS(n) in conjunction with mechanism-based stress studies in the elucidation of drug impurity structure: rapid identification of a process impurity in betamethasone 17-valerate drug substance.
    Li M; Lin M; Rustum A
    J Pharm Biomed Anal; 2008 Dec; 48(5):1451-6. PubMed ID: 18977106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis.
    Ruggenthaler M; Grass J; Schuh W; Huber CG; Reischl RJ
    J Pharm Biomed Anal; 2017 Feb; 135():140-152. PubMed ID: 28024262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of RP-UPLC method for the determination of darifenacin hydrobromide, its related compounds and its degradation products using design of experiments.
    Murthy MV; Krishnaiah Ch; Srinivas K; Rao KS; Kumar NR; Mukkanti K
    J Pharm Biomed Anal; 2013 Jan; 72():40-50. PubMed ID: 23146225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
    Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
    J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation.
    Thomas S; Mathela CS; Agarwal A; Paul SK
    J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.
    Háda V; Dubrovay Z; Lakó-Futó A; Galambos J; Gulyás Z; Aranyi A; Szántay C
    J Pharm Biomed Anal; 2013 Oct; 84():309-22. PubMed ID: 23177164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of new impurities of enalapril maleate on oxidation in the presence of magnesium monoperoxyphthalate.
    Toporisic R; Mlakar A; Hvala J; Prislan I; Zupancic-Kralj L
    J Pharm Biomed Anal; 2010 Jun; 52(2):294-9. PubMed ID: 20122808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
    Lalitha Devi M; Chandrasekhar KB
    J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of degradation products in stressed tablets of Rabeprazole sodium by HPLC-hyphenated techniques.
    Vasu Dev R; Sai Uday Kiran G; Venkata Subbaiah B; Suresh Babu B; Moses Babu J; Dubey PK; Vyas K
    Magn Reson Chem; 2009 May; 47(5):443-8. PubMed ID: 19173350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
    Thomas S; Chandra Joshi S; Vir D; Agarwal A; Rao RD; Sridhar I; Xavier CM; Mathela CS
    J Pharm Biomed Anal; 2012 Apr; 63():112-9. PubMed ID: 22361658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC.
    Rajana N; Devi DR; Kumar Reddy DN; Babu JM; Basavaiah K; Balakumaran K
    J Chromatogr Sci; 2020 Apr; 58(5):433-444. PubMed ID: 32134104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of LC-MS/TOF, LC-MS(n), NMR and LC-NMR in characterization of stress degradation products: Application to cilazapril.
    Narayanam M; Sahu A; Singh S
    J Pharm Biomed Anal; 2015; 111():190-203. PubMed ID: 25890215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.